A final discussion point is real-world applicability. Although PHAROS presents exceptional PFS, the modest difference between PFS and OS suggests that resistance remains a major hurdle. As with other ...

Dual art therapy, combining music and painting, significantly improved symptoms, cognitive function, and quality of life in ...

Celecoxib improves disease-free and overall survival in ctDNA-positive stage III colon cancer patients when combined with ...

As treatment for schizophrenia changes, LAIs are becoming increasingly important as maintenance therapy. Teva's pursuit of an ...

The IRA requires health plans serving the Part D market to cover all negotiated drugs, and it has been predicted that CMS ...

Zevaskyn, the first gene therapy for recessive dystrophic epidermolysis bullosa, showed significant wound healing in phase 3 ...

In another first, Sandoz launched in November 2025 the first FDA-approved biosimilar of Tysabri (natalizumab). Tyruko (natalizumab-sztn) is used to treat adult patients with relapsing multiple ...

Venclexta-azacitidine combination offered better responses with less hospitalization and lower symptom burden compared with ...

Early ctDNA clearance, combined with complete response on PET-CT, correlates with prolonged progression-free survival. ctDNA testing is minimally invasive and can be conducted repeatedly, offering a ...

RZV offers substantial clinical and economic benefits but has low uptake among adults aged 50 and older compared to other vaccines. By 2020, only 10.8% of adults aged 50 and older had completed both ...

A modified immunotherapy regimen for advanced melanoma showed a 49% response rate and extended median overall survival to 42 ...

High consumption of ultra-processed foods elevates the risk of early-onset colorectal cancer, highlighting the need for ...